Genetic transfer and expression of drug-resistance functions into haematopoietic stem and progenitor cells is a promising means to overcome both the acute and longterm side-effects of cytotoxic drugs in bone marrow. Here, we describe a functional analysis of a retroviral vector that co-expresses human cDNAs for multidrug resistance 1/P-glycoprotein (MDR1) and a double mutant of O 6 -alkylguanine-alkyltransferase (hATPA/GA) to high levels. The hATPA/GA protein contains two amino acid substitutions that render it resistant to compounds such as O 6 -benzylguanine that inhibit the wild-type protein which is often overexpressed in resistant tumour cells. Evidence for simultaneous drug resistance of genetically modified primary murine progenitor cells to colchicine or the podophyllotoxin etoposide, both covered by MDR1-mediated efflux activity, and the nitrosourea BCNU, which is counteracted by hATPA/GA, is presented using in vitro colony assays. Bone Marrow Transplantation (2000) 25, Suppl. 2, S71-S74.
Summary:
Genetic transfer and expression of drug-resistance functions into haematopoietic stem and progenitor cells is a promising means to overcome both the acute and longterm side-effects of cytotoxic drugs in bone marrow. Here, we describe a functional analysis of a retroviral vector that co-expresses human cDNAs for multidrug resistance 1/P-glycoprotein (MDR1) and a double mutant of O 6 -alkylguanine-alkyltransferase (hATPA/GA) to high levels. The hATPA/GA protein contains two amino acid substitutions that render it resistant to compounds such as O
6
-benzylguanine that inhibit the wild-type protein which is often overexpressed in resistant tumour cells. Evidence for simultaneous drug resistance of genetically modified primary murine progenitor cells to colchicine or the podophyllotoxin etoposide, both covered by MDR1-mediated efflux activity, and the nitrosourea BCNU, which is counteracted by hATPA/GA, is presented using in vitro colony assays. Bone Marrow Transplantation (2000) 25, Suppl. 2, S71-S74. Keywords: oncology; cancer chemotherapy; haematotoxicity; gene therapy; drug resistance; retroviral vectors Myelotoxicity represents a severe problem in the design of successful anti-cancer chemotherapy regimens, especially after intensive pretreatment of patients with or without bone marrow transplantation. Genetic transfer and expression of drug-resistance functions into haematopoietic stem and progenitor cells is a promising means to overcome both the acute and long-term deleterious effects of cytotoxic drugs in bone marrow. 3 Evidence for simultaneous expression of both resistance functions (MDR1 and hATPA/GA) is presented using in vitro colony assays of retrovirally transduced murine progenitor cells.
Materials and methods

Vector construction and establishment of packaging cells
The retroviral vector SF1MIO is similar to SF1MIH, 4 but contains the O 6 -BeG resistant mutant of human hAT, 3 instead of the wild-type cDNA. SF1MIO producers were established by transfection of safety-modified ecotropic packaging cells GP&env86. 20 g of retroviral vector plasmid and 2 g of a G418 resistance encoding plasmid DNA were used for electroporation. 5 Selection for stable integration was performed with G418 (Life Technologies, Paisley, UK) at 400 g/ml and subsequently with colchicine (Sigma-Aldrich, Deisenhofen, Germany) at 40 ng/ml. Single clones were isolated and expanded. Virus titre was analysed by supernatant infection of mouse fibroblasts SC1 and subsequent selection in colchicine.
Retroviral gene transfer in murine bone marrow cells
Murine bone marrow was harvested from 2-to 3-monthold C57BL/6J mice bred in the animal facility of the Heinrich-Pette-Institute under specific pathogen-free conditions. Femures and tibiae were prepared and flushed. 6 Mononuclear cells were stimulated in IMDM media containing 20% horse serum, supplemented with conditioned media containing murine interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF). After 2 days of culture, cells were plated in densities of 10 6 cells/ml on irradiated (5 Gy) confluent layers of cloned SF1MIO-transfected GP&env86 cells. After 48 h of coculture, suspension cells were harvested, washed, counted and plated as triplicates in supplemented media as above, but containing 0.33% final concentration (f.c.) DIFCO-agar. After 5 days of culture in a humidified CO 2 incubator, colonies were counted microscopically, regardless of treatment conditions. Only colonies comprised of at least 50 vital cells were scored.
Determination of drug resistance
The following cytotoxic agents were used for in vitro studies: colchicine (Sigma), etoposide, also known as VP-16, and BCNU (Bristol, Munich, Germany). Drugs were kept in aliquots as recommended by the supplier and added freshly to the cells in the desired concentrations. In some experiments, cells were exposed to drugs for 1 h in liquid culture containing 5 × 10 5 mononuclear cells harvested after retroviral transduction. Thereafter, cells were washed twice in phosphate buffered saline (PBS) before plating in colony assays containing drugs as indicated in Results.
Results
Vector cloning and establishment of producer cells
A schematic representation of the retroviral vector SF1MIO is shown in Figure 1 . MDR1 is expressed under control of cis-regulatory sequences of the FMEV retroviral vector. 7 hATPA/GA was placed 3Ј of the MDR1 transcription unit, with translation facilitated by insertion of an internal ribosomal entry site (IRES) derived from poliovirus, as described earlier for other cDNAs. 4, 8, 9 Negative control vectors were MO1L or MO3␦, expressing a lacZ/neoR fusion gene or the truncated nerve growth factor receptor, respectively. 7 These vectors were unable to confer resistance to the anticancer agents used in this study (data not shown). Vector producer cells were established as described in Material and methods. The cloned ecotropic SF1MIO-producers expressed human MDR1/P-glycoprotein and hATPA/GA to high levels (data not shown). Cell-free supernatants transferred a functional MDR1 gene to murine fibroblasts with titers of about 1 × 10 5 infectious units/ml. 
SF1MIO confers drug resistance to haematopoietic cells in vitro
Primary murine CFU-GM progenitor cells were adapted to growth in vitro in media supplemented with growth factors IL-3 and GM-CSF. After transduction by coculture on ecotropic producers of SF1MIO, cells were exposed to cytotoxic agents either for 1 h in vitro, or permanently in a 5-day colony assay, or both subsequently. Control cells were challenged under identical conditions, but transduced with vectors that do not confer cancer drug resistance (MO1L or MO3␦).
In various independent experiments, 15 to 30% of CFU-GM acquired clear multidrug resistance enabling survival upon exposure of colchicine at 30 ng/ml or VP-16 at 150 ng/ml administered as single agents in colony assays (Figure 2) . We also obtained SF1MIO-transduced colonies surviving exposure to BCNU, indicating functional expression of the hATPA/GA protein ( Figure 2 ). Shortterm exposure to BCNU was better tolerated than addition of this agent to the colony assay. This indicated that expression of the hATPA/GA protein from the IRES was limiting or that BCNU added at higher doses or for longer time periods led to an accumulation of toxic effects that could not be repaired by the hATPA/GA protein, such as alkylation of proteins, or DNA at sites different from the O 
Simultaneous drug resistance to combined chemotherapy with BCNU and MDR1-susceptible agents mediated by SF1MIO
To test whether genetic modification of primary haematopoietic progenitor cells with SF1MIO was able to protect from the combined toxicity of BCNU and MDR1 com- Figure 2 Single drug resistance mediated by gene transfer of SF1MIO in murine CFU-GM. Shown are the percentages of total colony-forming units (CFU) surviving drug exposure, given as mean values and standard deviations of two independent experiments, each performed in triplicates. VP-16 (CA), colony assay containing VP-16 at 150 ng/ml; BCNU (CA), colony assay containing BCNU at 5 g/ml; BCNU (1 h), colony assay in absence of drug after previous exposure of cells for 1 h to BCNU at 10 g/ml.
pounds, further experiments were performed. Cells were plated in soft-agar media containing VP-16 (150 ng/ml) or colchicine (30 ng/ml) or no drug immediately after shortterm exposure to BCNU. Roughly 20% of cells surviving exposure to BCNU for 1 h were also resistant to VP-16 or colchicine (Figure 3 ). This indicated that these cells had acquired dual and simultaneous drug resistance, under conditions that almost entirely eliminated growth of untransduced cells.
Finally, we tested whether BCNU-resistant cells could be enriched after previous selection based on the co-transferred MDR1-phenotype. Cells were first exposed to VP-16 and subsequently plated in BCNU-containing colony assays. This procedure completely extinguished control cells. In contrast, more than 20% of cells surviving exposure to VP-16 alone also were resistant to BCNU in the colony assay. Compared to the results achieved in the CFU-GM assay with BCNU alone (Figure 2 ), this represented a significant enrichment of BCNU-resistant cells. A higher enrichment could not be expected, because the concentration of VP-16 (500 ng/ml) during the 1 h exposure represented the inhibitory concentration resulting in death of 50% of control cells (IC 50 ).
Discussion
This study reveals that primary murine myeloid progenitors transduced with a single retroviral vector, SF1MIO, acquire dual and simultaneous resistance to chemotherapeutic agents covered by MDR1-encoded multidrug resistance, as shown for the podophyllotoxin VP-16 and colchicine, and to nitrosoureas, as exemplified with BCNU. This result is promising considering that a number of chemotherapeutic protocols combine drugs belonging to both resistance profiles, as in the treatment of multiple myeloma, large cell lymphoma, medulloblastoma, and certain solid tumours. 
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However, careful examination of the data indicates that further technological refinements would be required to achieve complete chemoprotection of all cells that were exposed to the gene transfer vector. Four drawbacks can be identified that might explain why this was not observed in the present study. The first is an incomplete gene transfer to target cells: less than 50% of cells were transduced in this study due to a limited vector titre; the second is caused by a partial genomic instability of the vector, generating a defective MDR1 transcription unit in at least 50% of transduced cells due to pregenome splicing; [8] [9] [10] the third is a still limited expression of both drug resistance genes in the bicistronic vector, as observed for other combinations of genes; 8, 9 the last can be attributed to residual drug toxicity that cannot be counteracted by the genes transduced, even when these are highly expressed. These drawbacks are addressed in our ongoing work.
The results presented here justify further testing of the concept of dual chemoprotection in murine animal models.
Together with further refinement of the vector technology and a careful choice of disease entities and appropriate combinations of drugs, this work might result in novel clinical trials that address the potential benefits and risks of genetically transferred combined chemoresistance.
